The Evidence Type refers to the type of clinical (or biological) association described by the Evidence Item’s clinical summary.

Understanding Evidence Types

Six Evidence Types are currently supported: Predictive (i.e. Therapeutic), Diagnostic, Prognostic, Predisposing, Oncogenic, and Functional. Each Evidence Type describes the clinical or biological effect a Molecular Profile (MP) has on the following: therapeutic response (Predictive), determining a patient’s diagnosis or disease subtype (Diagnostic), predicting disease progression or patient survival (Prognostic), disease susceptibility (Predisposing), or biological alterations relevant to a cancer phenotype (Oncogenic) or protein function (Functional). Selecting an Evidence Type has implications on available selections for Significance, which are detailed on the Evidence Significance page.





Evidence pertaining to a Molecular Profile’s effect on therapeutic response


Evidence pertaining to a Molecular Profile’s impact on patient diagnosis


Evidence pertaining to a Molecular Profile’s impact on disease progression, severity, or patient survival


Evidence pertains to a germline Molecular Profile’s role in conferring susceptibility to disease (including pathogenicity evaluations)


Evidence pertains to a somatic Molecular Profile’s involvement in tumor pathogenesis as described by the Hallmarks of Cancer


Evidence pertains to a Molecular Profile’s impact on gene product (e.g. protein) function

Extensive documentation for curating Evidence types is provided on the Curating Evidence page. Be sure to closly study the examples for each type.